Smart Innovation

Antimicrobial resistance (AMR)

AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible. 
AMR is considered the biggest global threat of Health and Food Safety.

AMR Insights

For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities. 

AMR Insights is for:

  • Researchers at Universities and University Medical Centers
  • Researchers at Research Institutes
  • R&D professionals in Pharma, Biopharma and Diagnostics companies
  • Entrepreneurs in start-up’s and spin off companies
  • Innovators, Venture Capitalists.

Latest Topics

  •   18 September 2020

    How Managing Data Effectively Helps Fight Antimicrobial Resistance

    The crisis of antibiotic resistance is making the discovery and development of new antibiotics crucial, and companies are teaming up to tackle the growing challenge.

    Read more...
  •   18 September 2020

    Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial

    Urinary tract infections (UTIs) are among the most prevalent microbial diseases and their financial burden on society is substantial.

    Read more...
  •   12 September 2020

    Peptilogics Receives FDA Orphan Drug Designation for Novel Peptide Therapy for the Treatment of Prosthetic Joint Infections

    The Orphan Drug Designation program grants orphan status to drugs intended for the treatment of a rare disease that affects fewer than 200,000 people in the US. Programs with Orphan Drug status may receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity.

    Read more...

More news related to Smart innovation

Please call me back

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!